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Abstract: There is variability in the reported effects of compounds on osteoblasts arising from 
differences in experimental design and choice of cell type/origin. This makes it difficult to discern a 
compounds action outside its original study and compare efficacy between compounds. Here, we 
investigated five compounds frequently reported as anabolic for osteoblasts (17Ά-estradiol 
(oestrogen), icariin, lactoferrin, lithium chloride, and menaquinone-4 (MK-4)) on human 
mesenchymal progenitors to assess their potential for bone tissue engineering with the aim of 
identifying a potential alternative to expensive recombinant growth factors such as bone 
morphogenetic protein 2 (BMP-2). Experiments were performed using the same culture conditions 
to allow direct comparison. The concentrations of compounds spanned two orders of magnitude to 
encompass the reported efficacious range and were applied continuously for 22 days. The effects on 
the proliferation (resazurin reduction and DNA quantification), osteogenic differentiation (alkaline 
phosphatase (ALP) activity), and mineralised matrix deposition (calcium and collagen 
quantification) were assessed. Of these compounds, only 10 µM MK-4 stimulated a significant 
anabolic response with 50% greater calcium deposition. Oestrogen and icariin had no significant 
effects, with the exception of 1 µM icariin, which increased the metabolic activity on days 8 and 22. 
1000 µg/mL of lactoferrin and 10 mM lithium chloride both significantly reduced the mineralised 
matrix deposition in comparison to the vehicle control, despite the ALP activity being higher in 
lithium chloride-treated cells at day 15. This demonstrates that MK-4 is the most powerful stimulant 
of bone formation in hES-MPs of the compounds investigated, highlighting its potential in bone 
tissue engineering as a method of promoting bone formation, as well as its prospective use as an 
osteoporosis treatment. 
Keywords: matrix mineralisation; osteoblasts; bone formation; mesenchymal stem cells; 
osteoporosis; bone tissue engineering; menaquinone-4; vitamin K 
 
1. Introduction 
There is a need for new anabolic compounds in the field of bone tissue engineering to enhance 
the rate of bone formation on scaffolds and to improve tissue regeneration. Under standard 
osteogenic culture conditions with media supplemented with dexamethasone, Ά-glycerophosphate, 
and ascorbic acid [1], it can take months to years for scaffolds to become fully mineralised and bone-
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like [2]. Although osteogenesis can be enhanced through the use of growth factors such as bone 
morphogenetic protein 2 (BMP-2), their use is not without limitations. The major adverse side effect 
of BMP-2 treatment is ectopic bone formation due to leakage from the implant site; therefore, loading 
tissue engineering scaffolds for clinical treatments with unconstrained BMP-2 is not an ideal solution 
[3]. Furthermore, the response of human mesenchymal stem cells (MSCs) to BMP-2 is not consistent 
between donors [4], and the cost of using recombinant proteins is prohibitive to widespread clinical 
use.  
This need has resulted in numerous compounds being tested for anabolic effects on bone, many 
of which have been described in the literature as osteogenic. However, the lack of standardisation 
between laboratories and experiments has resulted in conflicting information about these effects. For 
example, in the case of oestrogen, it has been shown to both accelerate [5] and slow down [6] 
osteoblast proliferation, upregulate alkaline phosphatase activity [6] but suppress osteocalcin 
production [6,7], and enhance [8], not affect [9], or only augment mineralisation when applied 
intermittently [5]. This variation makes it difficult to predict the action of each compound outside the 
original study and to compare the relative efficacy between therapeutics.  
These varied findings arise from numerous factors. Some are unavoidable; for example, it is 
unreasonable to assume that all laboratories could use identical media formulations. Another source 
of variability is that separate studies investigate dissimilar concentrations of therapeutics and use 
different assays and time points to assess outcomes. Whilst this renders direct comparisons 
unreliable, it still allows for more general comparisons to be made; for example, was the 
differentiation or matrix production still enhanced?  
The final and perhaps most important source of variability is the use of different cell lines to 
represent the cell type of interest and donor variability in primary cells. On the proviso that multiple 
donors are tested within the same study, donor variability is desirable as it represents the wider 
human population; with single donor studies it cannot be ascertained whether the observed effects 
are donor-specific or not. Animal-derived cell lines are often used in lieu of human ones in cell 
culture, but genetic differences mean that observed responses cannot be assumed to also occur in 
human cells. Additionally, using osteoblasts as an example cell type, osteosarcoma cells such as MG-
63 and Saos-2 are often reported as being osteoblasts or osteoblast-like despite the fact that they have 
abnormal, cancerous growth characteristics and cannot mirror the whole range of osteoblast 
phenotypic changes. Furthermore, there are inconsistencies in their reported ability to deposit a 
mineralised extracellular matrix, including some reports stating that a mineralised matrix is not 
deposited by these cell types [10,11]. Therefore, it is difficult to discern whether the effects reported 
on these cell lines are transferable to primary osteoblastic cells. Importantly, these sources of 
variability combine and result in a collection of literature that states that the same compound can 
promote, inhibit, or have no effect on bone formation.  
In this study, in order to minimise this variation and improve reproducibility, commercially 
available Cellartis® human embryonic stem cell-derived mesenchymal progenitor cells 002.5 (hES-
MPs) were used for all experiments in the precise recommended medium. This cell type was selected 
for two reasons; first, the commercial availability allows for the experiments to be more reproducible 
outside the original laboratory in comparison to primary cells; and second, it was selected due to its 
extensive use as a model osteoblast-lineage cell in tissue engineering studies. This cell line is a 
homogeneous, robust source of mesenchymal progenitors that has been demonstrated to be well 
representative of adult-derived mesenchymal stem cells (MSCs) and can be differentiated into 
osteogenic, chondrogenic, and adipogenic lineages [12,13]. With regards to using it as a model 
osteoblast-lineage cell, hES-MPs differentiate from mesenchymal progenitors into osteoblasts under 
osteogenic culture conditions. There is increasing alkaline phosphatase (ALP) activity over time, the 
deposition of mineralised extracellular matrix, expression of osteocalcin, osteopontin and MSC 
markers CD146, CD105, and CD90, and overall gene expression levels highly similar to adult MSCs 
[12,14,15]. Previously, they have been used in numerous bone tissue engineering studies [1623], the 
development of bioreactors [24], assessments of the effects of mechanical, chemical, and geometrical 
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differentiation cues [2528], and for bone toxicity testing [29] demonstrating their suitability for this 
study.  
Here, five compounds (17Ά-estradiol (oestrogen), icariin, lactoferrin, lithium chloride, and 
menaquinone-4), identified in the literature as having an anabolic effect on osteoblasts, are compared 
at concentrations over two orders of magnitude encompassing the reported efficacious range. 
Oestrogen, icariin (a phytoestrogen), and lactoferrin are reported to promote osteoblast proliferation 
and differentiation. Treatment with lithium chloride is associated with a higher bone mineral density 
and reduced fracture risk, and menaquinine-4 is a form of vitamin K that is reported to stimulate 
osteoblast differentiation and that facilitates mineralisation [5,3043]. An identical dosing regimen 
and cell culture protocol are used for each compound to allow direct comparisons to be made, with 
the proliferation, osteogenic differentiation, and mineralised extracellular matrix deposition being 
assessed. Although these compounds are less commonplace than better known promoters of 
osteogenesis such as bone morphogenetic protein 2 (BMP-2), any verified anabolic effect would 
represent a cheaper, more accessible approach to improving bone formation in the field of tissue 
engineering and a potential therapeutic for conditions such as osteoporosis. 
2. Materials and Methods  
All materials were sourced from Sigma-Aldrich, UK, unless otherwise stated. 
2.1. Cell Culture 
Cellartis® human embryonic stem cell-derived mesenchymal progenitor cells 002.5 (hES-MPs, 
Takara-Bio, France) were used for all cell culture experiments (passage 67). The cells were passaged 
in gelatin coated flasks at 37 °C, 5% CO2 and >90% humidity in the recommended expansion media 
(EM): basal media (BM, Dulbeccos Modified Eagle Medium (DMEM, Gibco, UK), supplemented 
with 10% qualified, heat inactivated, US origin foetal bovine serum (FBS, Gibco, UK, cat# 16140), 
100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco, UK)), supplemented with 4 ng/mL basic 
fibroblast growth factor (FGF, Peprotech, UK).  
For all experiments, hES-MPs were seeded in gelatin-coated 24-well plates at 30,000 cells/cm2 in 
basal media and left overnight to attach. Following a metabolic activity assay on day 1, cells were 
maintained in osteogenesis induction media (OIM: BM supplemented with 50 µg/mL ascorbic acid 
2-phosphate (AA2P), 5 mM beta-glycerolphosphate (ΆGP), and 100 nM dexamethasone) containing 
the appropriate compound for the remainder of the experiment. Full media changes were performed 
three times a week, with the metabolic activity determined on days 1, 8, 15, and 22, the alkaline 
phosphatase activity and total DNA measured on day 15, and the calcium and collagen deposition 
quantified on day 22.  
2.2. Compound Preparation 
Five different compounds were compared in this study: lactoferrin, lithium chloride, 17Ά-
estradiol (oestrogen), icariin, and menaquinone-4 (MK-4). Each was applied at three concentrations 
spanning three orders of magnitude in order to encompass the range reported as anabolic in the 
literature (Table 1). The vehicle concentration was controlled for all conditions. 
To create stock solutions, lactoferrin from bovine colostrum (cat# L4765, ~90 kDa) was dissolved 
in BM at 5 mg/mL, and lithium chloride (cat# L9650) was dissolved in BM at 1 M. Oestrogen, icariin, 
and MK-4 have poor solubility in aqueous solutions such as culture media. Therefore, 17Ά-estradiol 
(cat# E2758) was dissolved in ethanol (Fisher Scientific, UK), and then diluted in BM to a final 
concentration of 10 µM 17Ά-estradiol and 2% ethanol. Icariin and MK-4 were both dissolved in 
dimethyl sulfoxide (DMSO) at 10 mM. All stock solutions were sterilised by 0.2 µM filtration using 
ultra-low adsorption polyether sulfone filters (Whatman® Puradisc), divided into single-use aliquots 
and stored at 20 °C. 
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Table 1. The different compounds and concentrations investigated. 
Compound Low Medium High Citation 
Oestrogen 1 nM 10 nM 100 nM [5,30,31] 
Icariin 100 nM 1 µM 10 µM [3235] 
Lactoferrin 10 µg/mL (~111 nM) 100 µg/mL (~1.11 µM) 1 mg/mL (~11.11 µM) [3638] 
Lithium Chloride 100 µM 1 mM 10 mM [3941] 
Menaquinone-4 100 nM 1 µM 10 µM [42,43] 
2.3. Metabolic Activity  
The cell metabolic activity was evaluated by resazurin reduction (RR). Culture media was 
exchanged for RR working solution (10 vol% RR stock solution (1 mM resazurin sodium salt in 
deionised water (diH2O)) in BM), and the well plate was wrapped in foil and incubated for 4 hours. 
200 µL of the reduced solution was transferred in triplicate to a 96-well plate and read on a plate 
reader (Tecan infinite 200-pro) at Ώex: 540 nm and Ώem: 590 nm. The wells were rinsed with phosphate 
buffered saline (PBS) before adding fresh medium. 
2.4. Alkaline Phosphatase Activity and DNA Quantification 
The alkaline phosphatase (ALP) activity determination and total DNA quantification were 
performed on cell lysates on day 15. To digest, the media was removed and the wells were washed 
twice with PBS. 1 mL of cell digestion buffer (10 vol% cell assay buffer (1.5 M Tris-HCl, 1 Mm ZnCl2, 
1mM MgCl2 in diH2O), 1%Triton-X100 in diH2O) was added to the wells and refrigerated overnight. 
The well plates were then freeze-thawed three times (80 °C/37 °C) before scraping the wells and 
transferring the contents to microcentrifuge tubes. Lysates were centrifuged at 6700 RCF for 5 
minutes before homogenising the supernatant.  
The ALP activity was determined using the PierceTM PNPP substrate kit (ThermoFisher 
Scientific, UK) according to the manufacturers instructions. Briefly, 20 µL of lysate was combined 
with 180 µL of substrate (p-nitrophenol phosphate, pNPP) in a 96-well plate. The change in 
absorbance was measured using a plate reader (Tecan infinite 200-pro) at a wavelength of 405 nm 
every 90 seconds for 45 min. The ALP activity is expressed as nmol of p-nitrophenol per minute 
(nmol pNP/min), assuming that one absorbance value equals 19.75 nmol of product. This activity was 
normalised to the total DNA content per lysate. 
DNA was quantified using the Quant-iTTM high sensitivity dsDNA kit (ThermoFisher Scientific, 
UK), according to manufacturers instructions. Briefly, 10 µL of lysate was combined with 90 µL of 
substrate in a black 96-well plate. The plates were then shaken to aid the DNA-substrate conjugation, 
left at room temperature for 10 minutes, then shaken again before measuring the fluorescence (膏結捲: 
485 nm, 膏結兼: 535 nm). The shaking and fluorescence were performed and measured using a plate 
reader (Tecan infinite 200-pro). The fluorescence was converted to ng of DNA using a standard curve 
and was scaled to the total lysate volume.  
2.5. Calcium and Collagen Quantification 
The wells were fixed by removing the culture media, washing twice with PBS, adding 3.7% 
formaldehyde for 20 minutes, then washing twice in diH2O. The calcium quantification was 
performed by Alizarin Red S (ARS) staining. ARS was dissolved at 1 w/v% in diH2O, filtered (0.45 
µm), and the pH was adjusted to 4.1. The wells were stained for 30 minutes before washing away 
residual ARS with diH2O. The wells were air-dried and photographed before destaining with 1 mL 
of 5% perchloric acid. 150 µL was then transferred in triplicate to a 96-well plate and read at an 
absorbance of 405 nm. (Tecan infinite 200-pro). The concentration of ARS was determined via a 
standard curve. 
After calcium staining, the wells were washed again with diH2O before staining for collagen 
with direct red 80 (DR80). DR80 was dissolved in saturated picric acid at 0.1 w/v% and filtered (0.45 
µm). The wells were stained for 1 hour before washing away residual DR80 with diH2O. The wells 
Bioengineering 2020, 7, 12 5 of 19 
 
were air-dried and photographed before destaining with 1 mL of 0.2 M sodium hydroxide:methanol 
in 1:1 ratio. 150 µL was then transferred in triplicate to a 96-well plate and read at an absorbance of 
540 nm. (Tecan infinite 200-pro). The concentration of DR80 was determined via a standard curve.  
2.6. Statistical Analysis 
All statistical analyses were performed in GraphPad Prism (version 7.00). For the resazurin 
reduction assays, the results were normalised to the mean of the vehicle control at each time point 
for each repeat. Significant differences were evaluated by a two-way analysis of variance (ANOVA) 
with Dunnetts multiple comparisons test comparing each compound concentration to the vehicle 
control. For all other assays, the results were normalised to the mean of the vehicle control for each 
repeat. Given that not all of the groups fitted a Gaussian distribution (Shapiro-Wilk normality test), 
significant differences were evaluated via the Kruskal-Wallis test with Dunns multiple comparisons 
test to compare each compound concentration to the vehicle control. All graphs are presented as the 
mean ± standard deviation, and significant differences are indicated on the graphs and in the legends. 
Differences were considered significant when p < 0.05 (*). Other p-values designated in this 
manuscript are ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  
3. Results 
3.1. Establishing the Baseline Response of hES-MPs to Osteogenic Conditions 
In each experimental plate, hES-MPs were cultured under standard osteogenic conditions 
(OIM), OIM with the appropriate vehicle control for the compound of interest, and OIM with the 
three compound concentrations. The data from cells cultured in OIM was collated across all 
experimental plates to establish a baseline response of hES-MPs to standard osteogenic conditions 
(Figure 1). As it has been previously demonstrated that hES-MPs do not undergo osteogenic 
differentiation when maintained in basal media, this was not repeated here [28,4447]. As expected, 
they proliferated to confluence and underwent differentiation into osteoblasts. On day 15, the total 
DNA per well was 717.9 ± 87.8 ng, and the ALP activity per well was 33.17 ± 3.72 nmol pNP/min, 
yielding a normalised ALP activity of 46.49 ± 4.82nmol pNP/min/pg DNA. In the third week of 
culture, hES-MPs began to deposit a mineralised, collagenous extracellular matrix. On day 22, the 
calcium deposition per well retained 435.8 ± 96.13 µg of ARS, and the collagen deposition per well 
retained 40.10 ± 8.99 µg of DR80. There was a high concordance between repeats for each assay used 
to establish a baseline response, demonstrating the reproducibility of the osteogenic differentiation 
of hES-MPs. Although the calcium deposition had a wide range between the minimum and 
maximum, only 4 values were below the 10th percentile, and the narrow interquartile range shows 
the low spread of the data.  
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Figure 1. The baseline response of hES-MPs to osteogenesis induction media (OIM) over 22 days. (A) 
The metabolic activity. Boxplots showing minimum, 1st quartile, mean, 3rd quartile and maximum 
for (B) the total DNA, (C) ALP activity, (D) normalised ALP activity, (E) calcium deposition, and (F) 
collagen deposition. (n = 48). Whole well images (diameter ~15 mm) and a high magnification phase 
contrast image (scale bar: 100 µm) show typical matrix deposition characteristics. 
3.2. Determination of Appropriate Concentration of the DMSO Vehicle  
Icariin and MK-4 are not readily soluble in aqueous media; therefore, it was necessary to identify 
the lowest concentration of DMSO that permitted the application of the highest required dose of the 
compound. It was identified that only at 1% DMSO were any of the analysis parameters significantly 
affected (Figure 2); therefore, either 0.1% or 0.01% DMSO would be acceptable vehicle control 
concentrations. However, a minimum of 0.1% DMSO was required to achieve a 10 µM concentration 
of MK-4. 17ɴ-estradiol also has a poor aqueous solubility and was therefore first dissolved in ethanol 
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before being diluted in BM. However, due to the very low final concentration of ethanol (0.02%) 
during the experiments, no effects were detectable (data not shown). 
 
Figure 2. The effect of DMSO normalised to 0% (horizontal dashed line). (A) The metabolic activity 
normalised to 0% at each time point, (B) D15 total DNA, (C) D15 normalised ALP activity, (D) D22 
ARS, (E) D22 DR80, and (F) representative whole well photographs of ARS and DR80 staining at each 
concentration (diameter ~15 mm). (n = 8). No significant effect on any parameter for 0.01% or 0.1%. 
At 1% DMSO, the metabolic activity was significantly reduced from D7 onwards, with ALP, DNA, 
mineral, and collagen also all being significantly lower. 
3.3. The Highest Concentrations of Lactoferrin and Lithium Chloride Significantly Reduce Metabolic 
Activity 
A comparison of the metabolic activities of hES-MPs cultured in OIM versus the vehicle controls 
was performed initially, finding no significant difference at any time point (Figure 3A). When 
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investigating the effects of compounds, the baseline metabolic activity was determined on day 1 prior 
to the initial application, then in each subsequent week until the end of the study. There were no 
differences in growth in the vehicle controls for each compound (Figure 3B). The concentrations of 
compound that caused a significant deviation from their respective vehicle control growth curve 
were lactoferrin at 1 mg/mL and lithium chloride at 10 mM (Figure 3E), which caused a significantly 
lower metabolic activity from day 14 onwards (p < 0.0001), and 1 µM icariin, which induced a 
significantly higher metabolic activity on days 8 and 22 (p < 0.05, Figure 3D).  
 
Figure 3. The effect of each compound and concentration on the metabolic activity. No significant 
difference in the metabolic activity for hES-MPs cultured in (A) OIM vs. BM/DMSO vehicle controls 
(n = 40), and (B) the vehicle controls for each compound, normalised to day 1 (n = 8). (CE) The effect 
of each compound at the (C) lowest, (D) middle, and (E) highest concentrations on the metabolic 
activity, normalised to their respective vehicle control at each time point (horizontal dashed line). (n 
= 8). Lactoferrin (1 mg/mL) and lithium chloride (10 mM) significantly reduced the metabolic activity 
from day 15 onwards (p < 0.0001). 1 µM icariin significantly increased the metabolic activity on days 
8 and 22 (p < 0.05). No other condition significantly deviated from the vehicle control growth curve. 
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3.4. Total DNA Confirms High Concentrations of Lactoferrin and Lithium Chloride Reduce Cell Number 
The total DNA was quantified on day 15 to compare to metabolic activity and normalise the ALP 
activity (Figure 4). The total DNA amounts per well for the vehicle controls were 723.0 ± 70.1 ng DNA. 
The total DNA correlated with the metabolic activity, with treatments of lactoferrin at 1 mg/mL and 
lithium chloride at 10 mM causing significantly reduced total DNA in comparison to their respective 
vehicle controls (p < 0.01).  
 
Figure 4. The effect of each compound and concentration on the total DNA per well at day 15, 
normalised to their respective vehicle control (horizontal dashed line). The treatment with lactoferrin 
(1 mg/mL) and lithium chloride (10 mM) significantly lowered the total DNA (p < 0.001 & p <0 .01, 
respectively). No other condition significantly deviated from the vehicle control. (n = 8). 
3.5. The Highest Concentrations of Lithium Chloride Significantly Enhance ALP Activity 
The alkaline phosphatase activity was quantified on day 15 as a marker of osteogenic 
differentiation (Figure 5). The normalised ALP activities for the vehicle controls were 32.34 ± 3.34 
nmol pNP/min/pg DNA. As with markers of cell number, only lactoferrin at 1 mg/mL and lithium 
chloride at 10 mM significantly differed from the vehicle control. However, whilst the normalised 
ALP activity was lower after the treatment with lactoferrin (p < 0.01), it was higher (two-fold) with 
lithium chloride (p < 0.01). In the case of lactoferrin, both the total ALP activity and total DNA were 
lower than the vehicle control, whereas the treatment with 10 mM lithium chloride resulted in a 
significantly higher total ALP activity despite the lower total DNA per well, hence the dramatic 
change (data not shown).  
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Figure 5. The effect of each compound and concentration on the normalised ALP activity at day 15, 
normalised to their respective vehicle control (horizontal dashed line). The treatment with lactoferrin 
(1 mg/mL) resulted in a significantly lower normalised ALP activity, whilst the treatment with lithium 
chloride (10 mM) elevated the normalised ALP activity by 100% (both p < 0.01). No other condition 
significantly differed from the vehicle control. (n = 8). 
3.6. Menaquinone-4 Significantly Increases Mineral Deposition 
The calcium deposition by ARS staining (Figure 6) and collagen deposition by DR80 staining 
(Figure 7) were quantified on day 22 to assess the mineralised matrix production. The total ARS and 
total DR80 per well for the vehicle controls were 421.8 ± 64.00 µg and 42.62 ± 5.98 µg, respectively. 
The treatment with lactoferrin at 1 mg/mL and lithium chloride at 10 mM both caused significantly 
less calcium to be deposited. Interestingly, phase contrast imaging reveals that although lactoferrin 
causes fewer and smaller mineral nodules to be formed, they appear normal in morphology. 
However, with lithium chloride, ARS staining is present throughout the well, but it appears much 
lighter/pinker macroscopically. At high magnifications, this is revealed to be due to calcium not 
depositing as nodules but as highly disordered, tangled, spaghetti-like structures. This is consistent 
with collagen deposition, where with lactoferrin a smaller quantity of normal collagen deposition is 
present, whereas with lithium chloride it appears speckled and broken up. The application of 10 µM 
MK-4 resulted in 50% more mineralisation (p < 0.05) with no effect on the collagen production, 
demonstrating an anabolic, osteogenic effect. All mineral and collagen staining images can be found 
in the Supplementary Materials.  
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Figure 6. (Top) The effect of each compound and concentration on the calcium deposition at day 22, 
normalised to their respective vehicle control (horizontal dashed line). The treatment with lactoferrin 
(1 mg/mL) and lithium chloride (10 mM) resulted in a significantly lower calcium deposition in 
comparison to the vehicle control (p < 0.001 & p < 0.01, respectively), whilst the MK-4 (10 µM) 
treatment resulted in a 50% greater calcium deposition (both p < 0.05). No other condition significantly 
deviated from the vehicle control. (n = 8). (Bottom) Representative whole well images (diameter ~15 
mm) and high magnification (40×) phase contrast images (diameter 200 µm) of ARS staining of each 
compound at the highest concentration applied. 
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Figure 7. (Top) The effect of each compound and concentration on the collagen deposition at day 22, 
normalised to their respective vehicle control (horizontal dashed line). Lactoferrin (1 mg/mL) and 
lithium chloride (10 mM) significantly diminished the collagen deposition (p < 0.01 & p < 0.05, 
respectively). No other condition significantly deviated from the vehicle control. (n = 8). (Bottom) 
Representative whole well images (diameter ~15 mm) and high magnification (40×) phase contrast 
images (diameter 200 µm) of DR80 staining of each compound at the highest concentration applied. 
4. Discussion 
In this study, five reportedly osteogenic compounds were compared under controlled 
conditions to allow for a direct comparison and to determine their relative osteogenic effects on hES-
MPs, a commercially available mesenchymal progenitor cell line that is a demonstrated model of 
adult MSCs. Our initial hypothesis was that these compounds would stimulate a bone-like matrix 
formation in vitro in these mesenchymal progenitors and have potential for use in bone tissue 
engineering, as well as for bone regeneration in vivo.  
Of the five compounds investigated here, only 10 µM menaquinone-4 (MK-4) resulted in a 
greater mineralised matrix deposition in hES-MPs. This agrees with recent similar studies that 
showed the same concentration of MK-4 elevated ALP activity and mineralisation in human amniotic 
fluid MSCs in a monolayer culture and in 3D scaffolds seeded with dental pulp stem cells [42,43]. 
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MK-4 is the most abundant isoform of menaquinone (vitamin K2) found in humans. Menaquinones 
have been shown to have both pro-osteoblastic and anti-osteoclastogenic attributes, and have 
received considerable attention for their positive effects on bone health [4851]. Due to MK-4 having 
the effect of improving the bone quality rather than only retaining the bone mineral density, it has 
been prescribed as a first line treatment for osteoporosis with vitamin D since 2011 [52], although this 
is not yet routine outside Japan. This work, in combination with other recent findings, demonstrates 
its potential as an anabolic therapeutic for bone and as a useful molecule in bone tissue engineering 
[53,54]. 
The proposed mechanism of action of MK-4 is through targeting the steroid and xenobiotic 
sensing nuclear receptor (SXR)/pregnane X receptor (PXR) in order to stimulate osteoblast 
differentiation and facilitate bone formation [5557], and the ·-carboxylation of non-collagenous 
bone proteins, specifically osteocalcin [58]. These processes promote differentiation and facilitate 
mineralisation; hence the increase in ALP activity and calcium deposition observed here and in other 
studies. Future work should investigate whether this mechanism of action is the reason for the 
increased mineralised matrix formation observed here. In this study, MK-4 only promoted 
mineralisation, with no observed increase in collagen deposition. However, if implemented for 
clinical use, this would not necessarily risk the same hypermineralisation and atypical fracture side 
effect observed with bisphosphonates [59], as tissue-engineered bone is often undermineralised in 
comparison to native bone, requiring extended time periods spanning many months of culture to 
achieve comparable levels of mineralisation [2,60,61].  
Nevertheless, this means that the findings for the four other compounds disagree with some of 
the previous literature. Potential reasons for these discrepancies will be explored here. The role of 
oestrogen in protecting the skeletal bone composition is well known. 17Ά-estradiol is the most 
abundant of the oestrogens and the primary type produced by the ovaries. Its decline post-
menopause is key in the pathogenesis of post-menopausal osteoporosis, primarily due to its effects 
on osteoclast-mediated bone resorption. In men, oestrogen is synthesised from testosterone via the 
enzyme aromatase. Oestrogen can act directly on monocytes, reducing their ability to become 
osteoclasts by disrupting the JNK pathway and upregulating apoptosis, as well as indirectly by 
reducing the RANKL:OPG ratio in osteoblast-lineage cells [62]. Whether oestrogen also has an 
anabolic effect on osteoblasts has been queried for over 20 years; however, in vitro studies have not 
definitively demonstrated that oestrogen is capable of increasing bone formation. There is evidence 
that it is pro-osteoblastic, for example by being anti-apoptotic [63] and by inducing ALP transcription 
[64]. However, anabolic effects have been predominantly reported in rodent and osteosarcoma cells 
[5,30], both of which are a poor representation of normal human MSCs/osteoblasts. One study did 
see anabolic effects in human MSCs [31], although it only used a single donor, indicating that the 
anabolic effects of oestrogen may be specific to the cell type or the donor, limiting its potential for use 
as an osteoblast-acting therapeutic. Interestingly, a recent study assessed 17Ά-estradiol synthesis from 
testosterone via aromatase by multiple donors of human MSCs. Up to 1 nM 17Ά-estradiol was 
synthesised by MSCs when cultured under osteogenic conditions with testosterone, comparable to 
the concentrations that were used here. No effect on the ALP activity was observed; however, 
osteogenic conditions with testosterone and the subsequent oestrogen production caused a 
significant increase in mineralisation. However, this effect was not compared to the direct addition 
of 17Ά-estradiol without testosterone, leaving it unclear whether the androgen or the oestrogen was 
the dominant cause of this increased mineralisation [65]. 
Icariin is the main flavonoid glycoside in the Epimedium herb and a phytoestrogen. Therefore, 
the similar finding to oestrogen that it had no detectable effect on hES-MPs other than a small increase 
in proliferation in the second and fourth week at 1 µM is not surprising. Interest in this molecule 
stems from its use in Chinese herbal medicine, and reports of its efficacy in promoting osteogenic 
differentiation and bone formation have been increasing in recent years. As with oestrogen, many of 
the studies demonstrating anabolic effects are performed using rodent cells [32,34], although it has 
also been reported to have an effect in a human foetal osteoblast cell line [66]. Interestingly, it has 
been shown in vivo that icariin is metabolised to icariside II and then icaritin prior to absorption and 
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that these metabolites have significantly greater anabolic effects on osteoblasts in vitro than icariin 
does [33]. As icariin metabolism cannot occur in these single cell type cultures, this could be a reason 
why an effect was not detected.  
Lactoferrin is an iron binding protein and member of the transferrin family found in high 
concentrations in milk and colostrum. It is thought to promote osteoblast proliferation and 
differentiation by interaction with the LRP1 receptor and activation of p42/44 MAPK signalling [67]. 
In contrast to previous studies [3638], lactoferrin was here found to have no effect on osteogenic 
differentiation at concentrations of 100 µg/mL and below, whilst 1000 µg/mL significantly reduced 
the proliferation, ALP activity, and mineralised matrix deposition. Where mineralised nodules did 
form at 1000 µg/mL, they appeared morphologically normal but were very small. Whilst bovine-
derived lactoferrin was used in this study with human-origin cells, it has previously been shown that 
bovine, human, and recombinant forms have comparable effects; therefore, this is unlikely to be the 
reason for not detecting any anabolic effect [36]. Previous reports of an increasing ALP activity in 
response to lactoferrin have shown an immediate increase after only 24 hours of exposure in normal 
human osteoblasts, MC3T3-E1, and primary murine osteoblasts [38,68], but the effects were not 
examined at later time points. A continuous exposure for 35 days at concentrations of up to 
1000 µg/mL showed a dose-dependent increase in mineralisation in the two murine cell types [68], 
although minimal mineralisation was observed in the absence of lactoferrin despite the use of 10 mM 
ΆGP. This high concentration of ΆGP has since been associated with the deposition of non-osteoblast 
mediated mineral due to a spontaneous precipitation of calcium phosphate [69]; therefore, it is 
possible that lactoferrin was influencing this mechanism rather than osteoblastic mineralisation. An 
increased matrix deposition has also been observed in the osteosarcoma cell line MG-63 [70,71], but 
these cancer cells are a poor representation of normal human MSCs/osteoblasts.  
Since the 1970s, lithium salts, specifically lithium chloride (LiCl), have been used as the gold 
standard treatment of bipolar disorders. It also has been found that patients treated with lithium for 
psychiatric disorders develop a higher bone mineral density [72], and the risk of bone fracture is 
reduced [73]. The precise mechanism by which lithium salts promote bone formation is yet to be 
elucidated, but one possibility is its inhibition of glycogen synthase kinase-3Ά and the consequent 
activation of canonical Wnt signalling [74]. In mesenchymal progenitors, this signalling inhibits 
adipogenesis and promotes osteoblastogenesis by regulating the expression of transcription factors 
such as RUNX2. However, another possible reason for the observed increase in BMD and reduced 
fracture risk in osteoporotic patients taking lithium is an increase in mechanosensitivity. Lithium 
chloride can lengthen the primary cilia, a mechanosensor present on most mammalian cells that 
bends in response to fluid flow [75], increasing its ability to transduce mechanical signals to cellular 
responses. Whilst a significant increase in the ALP activity was observed when 10 mM LiCl was 
applied in this study, the mineralised matrix deposition and cell number were significantly lower 
than the vehicle control. This effect is not surprising as serum concentrations this high are toxic, with 
the therapeutic serum concentration typically being 0.81.2 mM [39]. Furthermore, comparable LiCl 
concentrations have been shown to induce cell cycle G2/M phase arrest, potentially revealing why 
the metabolic activity and total DNA content were lower at 10 mM [76]. Although a mineralised 
matrix was deposited under 10 mM conditions, the collagen network and mineral were abnormal. 
Whilst collagen is normally produced in a swirl pattern, here it appeared to be more speckled and 
discontinuous. This resulted in spaghetti-like mineral patterns, rather than a typical nodule 
formation.  
The lack of response observed at lower concentrations may have been due to the influence of 
dexamethasone in the culture media, as this glucocorticoid (used to induce osteogenic differentiation) 
also acts via canonical Wnt signalling and the increase of RUNX2; therefore, its effects could have 
been masked [1]. Alternatively, the static culture employed in this study may have meant that the 
increase in mechanosensitivity that occurs after lithium chloride was not exploited and that, 
therefore, no increase in the mineralised matrix deposition was observed.  
In summary, of the five investigated compounds, only menaquinone-4 had an anabolic effect on 
hES-MPs. These findings are in close agreement with the recent literature that also investigated its 
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effects on highly relevant osteoblast-lineage cells and emphasises its potential as an anabolic 
compound that can be utilised in bone tissue engineering. The lack of a detectable effect of oestrogen 
and icariin and the negative effects of high concentrations of lactoferrin and lithium chloride, when 
compared to the existing literature, highlights the variability caused by differences in experimental 
design and the relevance of the cell type that is used.  
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